Literature DB >> 22380618

Expression of "a disintegrin and metalloproteinase-33" (ADAM-33) protein in laryngeal squamous cell carcinoma.

O Topal1, H Erinanc, C Ozer, E T Canpolat, S B Celik, S S Erbek.   

Abstract

OBJECTIVE: A disintegrin and metalloproteinase domain containing protein 33 (also known as ADAM-33) is a member of a matrix metalloproteinase family which mediates extracellular matrix remodelling and changes in cellular adhesion. This study aimed to evaluate expression of this protein in laryngeal squamous cell carcinoma, and to determine its correlation with patients' clinicopathological characteristics. SUBJECTS AND METHODS: Forty paraffin blocks of laryngeal carcinoma underwent immunohistochemical staining to detect "a disintegrin and metalloproteinase-33" expression. Case records were reviewed to determine patient characteristics.
RESULTS: All epithelial, vascular and stromal staining scores were significantly increased in tumour tissue compared with controls (p < 0.001). However, patients' clinical characteristics at the time of diagnosis, and their disease extent, did not correlate significantly with the immunohistochemical staining scores.
CONCLUSION: This study suggests that increased expression of "a disintegrin and metalloproteinase-33" may play a role in the pathogenesis of laryngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22380618     DOI: 10.1017/S0022215112000151

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  A Transcriptome-Wide Association Study Identifies Candidate Susceptibility Genes for Pancreatic Cancer Risk.

Authors:  Duo Liu; Dan Zhou; Yanfa Sun; Jingjing Zhu; Dalia Ghoneim; Chong Wu; Qizhi Yao; Eric R Gamazon; Nancy J Cox; Lang Wu
Journal:  Cancer Res       Date:  2020-09-09       Impact factor: 12.701

2.  Immunohistochemical study on ADAM33 in sinonasal inverted papillomas and squamous cell carcinomas of the larynx.

Authors:  Olga Stasikowska-Kanicka; Małgorzata Wągrowska-Danilewicz; Marian Danilewicz
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.